Engineered immune cells take aim at deadly brain tumors
NCT ID NCT05627323
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This early-phase trial is testing a new treatment called CHM-1101 for people with a type of brain cancer (glioblastoma) that has come back or is getting worse. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack tumor cells. The study will enroll 42 adults to find the safest dose and see if the therapy can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CHM-1101 CAR T-cells (immune cells engineered to target brain tumor cells)
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong
This is an early Phase 1b trial with only 42 participants, focused mainly on safety and dosing. It may not show strong effectiveness, and CAR T-cell therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
St. David's South Austin Medical Center - Sarah Cannon - Austin
Austin, Texas, 78704, United States